JOIN US AT ASENT2021 FOR A VIRTUAL CONFERENCE
Monday, February 22, 2021 – Thursday, February 25, 2021
ASENT invites you to join us February 22, 2021 through Thursday, February 25, 2021 for a virtual conference. Each day, scientific sessions will take place from 10:00am-1:00pm. You will find emerging neuroscience, posters and networking as you have at past meetings.
VIRTUAL CONFERENCE SCHEDULE
MONDAY |
|||
10:00am – 11:15am |
Symposium |
COVID and the nervous system as a basis medical and therapeutic challenge |
|
11:15am – 11:30am |
BREAK |
||
11:30am – 12:45pm |
Symposium Concurrent |
Obstacles and Opportunities in Alzheimer’s Disease Neurotherapeutics |
RNA editing and CRISPR technology: basic approaches and treatment implications for neurologic disease |
12:45pm – 1:00pm |
Comments from President |
||
TUESDAY |
|||
10:00am – 11:15am |
Symposium Concurrent |
New and Emerging Therapeutics for Epilepsy |
Dystonia: Genetics, pathophysiology, new targets and treatment |
11:15am – 11:30am |
BREAK |
||
11:30am – 12:45pm |
Pipeline |
PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline |
|
12:45pm – 1:00pm |
Comments from President |
||
WEDNESDAY |
|||
10:00am – 11:15am |
Symposium Concurrent |
Epigenetics in Neurodegenerative Disorders |
Emerging therapeutics in NeuroOncology |
11:15am – 11:30am |
BREAK |
||
11:30am – 12:45pm |
Pipeline |
PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline |
|
12:45pm – 1:00pm |
Comments from President |
||
THURSDAY |
|||
10:00am – 11:15am |
Symposium Concurrent |
Brain Organoids as Models of Neurological Disorders and Treatment |
Parkinson’s Disease New Approaches |
11:15am – 11:30am |
BREAK |
||
11:30am – 12:45pm |
Pipeline |
PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline |
|
12:45pm – 1:00pm |
Comments from President |
MONDAY
PRESIDENTIAL SYMPOSIUM: COVID and the nervous system as a basis medical and therapeutic challenge |
||
Symposium to cover 1918 flu pandemic, the 2020 covid-19 pandemic and neurological consequences. Stroke, olfactory (anosmia) and gustatory deficits and other neurological complications result from covid-19 infection. The delayed appearance of postencephalitic Parkinsonism in people surviving the 1918 flu and those contracting encephalitis lethargica around the same time indicate hidden, protracted risks may await those who survie viral pandemics. These topics and an update of neurological complications of covid-19 will be reviewed in this symposium. |
||
FACULTY |
||
10:00am – 10:30am |
KEYNOTE PRESENTATION: Neurological Consequences of Viral Pandemics including COVID-19 | Avindra Nath, MD, National Institute of Neurological Disorders and Stroke |
|
10:30am – 10:40am |
Live Q&A with KEYNOTE SPEAKER |
|
10:40am – 10:45am |
BREAK |
|
10:45am – 11:05am |
Invited Speaker |
|
11:05am – 11:25am |
Invited Speaker |
|
11:25am – 11:35am |
Live Faculty Panel Discussion and Q&A |
|
11:35am – 11:45am |
BREAK |
|
Obstacles and Opportunities in Alzheimer’s Disease Neurotherapeutics |
RNA editing and CRISPR technology: basic approaches and treatment implications for neurologic disease |
|
Speakers will address barriers to success, the use of natural history and investigation of drug repurposing in the search for solutions in Alzheimer’s Disease neurotherapeutics. |
Discussion of RNA editing as an improvement to CRISPR-related DNA editing, Molecular mechanims, clinical potentials of genome editing systems, applicability in neurological disorders. |
|
FACULTY |
FACULTY |
|
11:45am – 12:05pm |
Advances in Alzheimer’s Disease and Related Dementia Research | Eliezer Masliah, MD, National Institute on Aging |
Lloyd Mitchell |
12:05pm – 12:25pm |
Leveraging Dominantly Inherited Alzheimer Disease for Current and Future Alzheimer Therapeutics | Eric McDade, DO, Washington University School of Medicine in St. Louis |
TBD |
12:25pm – 12:45pm |
Barriers to success /opportunities in Alzheimer’s on the basis of prior or forthcoming trials | Dennis Selkoe, MD, Harvard Medical School and Brigham and Women’s Hospital |
TBD |
12:45pm – 1:00pm |
Live Faculty Panel Discussion and Q&A |
|
1:00pm – 1:15pm |
Closing comments from ASENT President |
Leveraging Unconventional (Big) Clinical Datasets for Treatment in Epilepsy |
Dystonia: Genetics, pathophysiology, new targets and treatment |
|
There is vast amount of data generated in the modern clinical practice of epilepsy, which is now more accessible than ever with the tools of Big Data. In this symposium, we will explore some of the efforts to tap this vast trove to advance the treatment of patients with epilepsy. |
Genetics, pathophysiology, new targets, treatment; looked at it from 3 different ways |
|
FACULTY |
FACULTY |
|
10:00am – 10:20am |
Natural Language Processing of EEG Reports to Learn Seizure Onsets | Christopher Lee-Messer, MD, PhD, Stanford University |
Dystonia Genes & Mechanisms | Hyder A. (Buz) Jinnah, MD, Emory School of Medicine |
10:20am – 11:40am |
Discovering Genotype-Phenotype Correlations Hidden in the EMR | Colin Ellis, MD, Children’s Hospital of Philadelphia |
Pathophysiology in Dystonia | Mark Hallett, MD, National Institute of Neurological Disorders and Stroke |
10:40am – 11:00am |
Applying artificial intelligence to epilepsy care: from scanner to bedside | Ezequiel Gleichgerrcht, MD, PhD, Medical University of South Carolina |
New Targets and Treatments in Dystonia | Susan Fox, MB ChB, MRCP, PhD, University of Toronto |
11:00am – 11:15am |
Live Faculty Panel Discussion and Q&A |
Live Faculty Panel Discussion and Q&A |
11:15am – 11:30am |
BREAK |
|
PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline |
||
11:30am – 12:30pm |
6 presentations each day/10 minutes each |
|
12:30pm – 12:45am |
Live Faculty Panel Discussion and Q&A |
|
12:45pm – 1:00pm |
Closing comments from ASENT President |
Physiological markers and epigenetic risk factors in neurodegenerative disorders |
Emerging therapeutics in NeuroOncology |
This session will cover the physiological markers of stress and aging, epigenetic regulation of myelination and demyelination, and MS susceptibility variants exert local and distal effects on the T cell epigenome. |
Glioblastoma Multiforme (GBM) is one of the most common and particularly aggressive forms of brain tumors of primarily glial cell origin. GBM is an incurable disease with few treatment advances for many years. Speakers will discuss new potential treatments and development in the field of GBM and other neuro-oncology diseases |
FACULTY |
FACULTY |
Multiple sclerosis susceptibility variants exert local and distal effects on the T cell epigenome | Philip deJager, MD, PhD, Columbia University |
New horizons for TTFields in neuro-oncology | Moshe Giladi, PhD, MBA, Novocure, Ltd. |
Physiological markers of stress and aging | David Ziegler, PhD, University of California, San Francisco |
Selinexor, Selective Inhibitor of Nuclear Export (SINE) compound in neuro-oncology | Paul Duic, MD, Karyopharm |
Epigenetic regulation of myelination and remyelination | Patrizia Casaccia, MD, PhD, Icahn School of Medicine |
Using the Mayo GBM PDX collection as a platform for developing novel combination therapies for GBM | Jann Sarkaria, MD, Mayo Clinic |
PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline |
|
6 presentations each day/10 minutes each |
Brain Organoids as Models of Neurological Disorders and Treatment |
Parkinson’s Disease New Approaches |
Speakers will describe the technology behind creating three-dimensional cell clusters that resemble peripheral and central nervous tissue, and how these CNS and PNS models show phenotypes consistent with CNS tissue, and diseases that plagued donors of the progenitor cells used to make these cell systems. The use of organoids to evaluate known and novel therapeutic agents, including gene therapies, will also be shown. |
Speakers will look at Stem cells, C-ABL therapy, Exercise in the context of Parkinson’s Disease therapeutic gaps and developments. |
FACULTY |
FACULTY |
Modelling physiology and disease with brain organoids | Thomas Hartung, MD, Johns Hopkins University |
Stem cells therapy in Parkinson’s Disease | |
Gaia Skibinski, PhD, System1 Biosciences |
Disease modification of Parkinson’s Disease through oral kinase inhibitor therapy | Milton Werner, PhD, Inhibikase Therapeutics |
Emily Lee, PhD, National Institute on Aging |
Therapeutically Beneficial Effects of Exercise on Parkinson’s Disease | Daniel Corcos, PhD, Northwestern Medicine |
PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline |
|
6 presentations each day/10 minutes each |